Skip to main content
Emcure Pharmaceuticals Limited logo

Emcure Pharmaceuticals Limited — Investor Relations & Filings

Ticker · EMCURE ISIN · INE168P01015 LEI · 335800WYB6OIBY9EOZ42 BSE.NS Manufacturing
Open in API
Filings indexed 201 across all filing types
Latest filing 2024-08-06 Regulatory Filings
Country IN India
Listing BSE.NS EMCURE

About Emcure Pharmaceuticals Limited

https://www.emcure.com

Emcure Pharmaceuticals Limited is a research-driven global pharmaceutical organization engaged in the development, manufacturing, and marketing of a broad range of differentiated pharmaceutical products. The company maintains a diverse portfolio across several key therapeutic areas, including gynaecology, cardiovascular, oncology, anti-infectives, and HIV/AIDS. With a strong emphasis on research and development, Emcure operates multiple state-of-the-art manufacturing facilities and R&D centers globally. Its business model focuses on complex generics and innovative formulations, serving healthcare needs in over 70 countries. The company is recognized for its vertically integrated operations and commitment to high-quality standards, catering to both regulated and emerging markets worldwide.

Recent filings

Filing Released Lang Actions
Board Meeting — EMCURE PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 13-Aug-2024 to inter-alia consider and approve the Unaudited Financial results of the Compan…
Regulatory Filings
2024-08-06 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document text is extremely short (384 characters) and contains only header information related to stock exchanges and script symbols. There is no substantive content, financial data, or report details. It appears to be a brief announcement or header without any report or detailed filing. Given the lack of content and the nature of the text, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous filings that do not fit other categories.
2024-08-06 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing Emcure Pharmaceuticals' signing of a Power Purchase Agreement (PPA) with Sunsure Energy for solar power. It focuses on sustainability initiatives and renewable energy commitments. There is no financial data, regulatory filing, or report attached or referenced as being published. The content is an announcement of a corporate sustainability initiative rather than a financial report, management change, or regulatory filing. Therefore, it fits best under the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2024-07-25 English
Acquisition
Capital/Financing Update Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (NSE and BSE) under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It announces an acquisition transaction involving Emcure Pharmaceuticals Limited and its subsidiary acquiring shares in Sunsure Solarpark Twelve Private Limited. The document provides detailed information about the acquisition, including the target entity, nature of the transaction, consideration, percentage acquired, and background of the acquired entity. There are no financial statements or detailed financial performance data presented, nor is this a report or presentation. The document is a regulatory announcement of a material event (acquisition) as required by SEBI Listing Regulations. Therefore, it fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as acquisitions.
2024-07-25 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal disclosure letter addressed to stock exchanges, informing about the authorized Key Managerial Personnel for materiality determination and disclosure purposes under SEBI regulations. It does not contain financial data, report content, or meeting results. It is a regulatory compliance announcement related to company disclosures rather than a financial report, management change announcement, or voting result. The document length is short (1973 characters), and it is a notification under Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which typically falls under general regulatory announcements. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-07-24 English
Trading Window
Regulatory Filings
2024-07-10 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.